1 / 2

Gamma-1: Five Year Follow-up Vascular Gamma Brachytherapy vs placebo for In-stent Restenosis in Native Coronary Lesions

Gamma-1: Five Year Follow-up Vascular Gamma Brachytherapy vs placebo for In-stent Restenosis in Native Coronary Lesions. MACE: Death, MI or TLR at 5 years. p = 0.380. p = 0.254. p = 0.064. %. p = 1.000. Gamma-1: Five Year Follow-up.

rhoswen
Download Presentation

Gamma-1: Five Year Follow-up Vascular Gamma Brachytherapy vs placebo for In-stent Restenosis in Native Coronary Lesions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gamma-1: Five Year Follow-upVascular Gamma Brachytherapy vs placebo for In-stent Restenosis in Native Coronary Lesions MACE: Death, MI or TLR at 5 years p = 0.380 p = 0.254 p = 0.064 % p = 1.000

  2. Gamma-1: Five Year Follow-up • Among patients treated with gamma brachytherapy or placebo for in-stent restenosis in native coronary lesions, there were no statistically significant differences in MACE, TLR, or TVR at five-years. • The risk of recurrent MI tended to be higher among patients treated with gamma brachytherapy (p=0.06) • While there was a clinical benefit at 9 months for gamma brachytherapy, these five-year results demonstrate no significant benefit of gamma brahcytherapy consistent with a “late catch-up” or delay in restenosis among these patients.

More Related